Michigan Institue of Urology, P.C.

Michigan Institute of Urology is a healthcare provider specializing in urologic care, offering innovative treatments for conditions like prostate and bladder cancer, while focusing on patient-centered services across Southeast Michigan. Founded in 1967 and headquartered in St. Clair Shores, Michigan, the Michigan Institute of Urology provides comprehensive urologic services. It was acquired by Solaris Health, LLC in November 2021, which aims to expand its operational reach.

The CEO is Mitchell Hollander, who has played a significant role in the company's development. Michigan Institute of Urology (MIU) specializes in comprehensive urologic care, offering a range of innovative treatments and procedures tailored to address conditions such as prostate cancer, bladder cancer, benign prostatic hyperplasia (BPH), and kidney stones, among others. The institute's flagship service, low-dose rate brachytherapy with Palladium-103, is a minimally invasive, one-time outpatient procedure designed to treat prostate cancer effectively. MIU employs a leading research team that continuously evaluates new medications and treatment methods to enhance patient outcomes in urology.

The institute serves a diverse clientele across Southeast Michigan, providing personalized care through its network of over 60 providers across 15 locations. MIU's commitment to advancing urology extends beyond traditional treatments, incorporating the latest clinical research and technology to ensure optimal patient care. Michigan Institute of Urology conducts its business primarily through direct patient services, focusing on outpatient procedures and clinical consultations. Revenue streams arise from various urologic services, including specialized treatments for conditions like BPH and prostate cancer, which patients can access through appointments with MIU urologists.

The institute operates on a fee-for-service model, where clients pay for individual procedures and consultations. Additionally, MIU may engage in partnerships with clinical trials, contributing to its revenue while fostering advancements in urologic research. As a provider of advanced urologic care, MIU is positioned to maintain a steady flow of revenue through its extensive service offerings, catering to a substantial patient base in the region. Following its acquisition by Solaris Health, LLC in November 2021, Michigan Institute of Urology aims to accelerate its expansion plans.

The acquisition will facilitate the development of new urologic treatments and enhance its service offerings. MIU is also looking to expand into additional geographic markets within the Midwest by 2024, leveraging the resources and expertise of Solaris Health to support these initiatives.